The influence of monoclonal antibodies for cancer treatment on the endocrine system
References
- Agata Y., Kawasaki A., Nishimura H., Ishida Y., Tsubata T., Yagita H., Honjo T.: Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol., 1996; 8: 765–772
- Arima H., Iwama S., Inaba H., Ariyasu H., Makita N., Otsuki M., Kageyama K., Imagawa A., Akamizu T.: Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: Clinical guidelines of the Japan Endocrine Society. Endocr. J., 2019; 66: 581–586
- Armand P., Chen Y.B., Redd R.A., Joyce R.M., Bsat J., Jeter E., Merryman R.W., Coleman K.C., Dahi P.B., Nieto Y., LaCasce A.S., Fisher D.C., Ng S.Y., Odejide O.O., Freedman A.S., et al.: PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood, 2019; 134: 22–29
- Bavencio – Summary of Product Characteristics. https://www.ema.europa.eu/en//documents/product-information/bavencio-epar-product-information_en.pdf (25.09.2020)
- Bhasin S., Brito J.P., Cunningham G.R., Hayes F.J., Hodis H.N., Matsumoto A.M., Snyder P.J., Swerdloff R.S., Wu F.C., Yialamas M.A.: Testosterone therapy in men with hypogonadism: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab., 2018; 103: 1715–1744
- Bornstein S.R., Allolio B., Arlt W., Barthel A., Don-Wauchope A., Hammer G.D., Husebye E.S., Merke D.P., Murad M.H., Stratakis C.A., Torpy D.J.: Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab., 2016; 101: 364–389
- Carlé A., Pedersen I.B., Knudsen N., Perrild H., Ovesen L., Andersen S., Laurberg P.: Hypothyroid symptoms fail to predict thyroid insufficiency in old people: A population-based case-control study. Am. J. Med., 2016; 129: 1082–1092
- Caturegli P., Di Dalmazi G., Lombardi M., Grosso F., Larman H.B., Larman T., Taverna G., Cosottini M., Lupi I.: Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: Insights into pathogenesis from an autopsy series. Am. J. Pathol., 2016; 186: 3225–3235
- Caturegli P., Newschaffer C., Olivi A., Pomper M.G., Burger P.C., Rose N.R.: Autoimmune hypophysitis. Endocr. Rev., 2005; 26: 599–614
- Cha E., Klinger M., Hou Y., Cummings C., Ribas A., Faham M., Fong L.: Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci. Transl. Med., 2014; 6: 238ra70
- Chabner B.A., Roberts T.G. Jr.: Timeline: Chemotherapy and the war on cancer. Nat. Rev. Cancer, 2005; 5: 65–72
- Chalan P., Di Dalmazi G., Pani F., De Remigis A., Caturegli P.: Thyroid dysfunctions secondary to cancer immunotherapy. J. Endocrinol. Invest., 2018; 41: 625–638
- Chamberlain J.J., Rhinehart A.S., Shaefer C.F. Jr, Neuman A.: Diagnosis and management of diabetes: Synopsis of the 2016 American Diabetes Association standards of medical care in diabetes. Ann. Intern. Med., 2016; 164: 542–552
- Chang L.S., Barroso-Sousa R., Tolaney S.M., Hodi F.S, Kaiser U.B., Min L.: Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr. Rev., 2019; 40: 17–65
- Chau C.H., Steeg P.S, Figg W.D.: Antibody-drug conjugates for cancer. Lancet, 2019; 394: 793–804
- Corsello S.M., Barnabei A., Marchetti P., De Vecchis L., Salvatori R., Torino F.: Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab., 2013; 98: 1361–1375
- Darvin P., Toor S.M., Nair V.S., Elkord E.: Immune checkpoint inhibitors: Recent progress and potential biomarkers. Exp. Mol. Med., 2018; 50: 1–11
- De Filette J., Andreescu C.E., Cools F., Bravenboer B., Velkeniers B.: A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm. Metab. Res., 2019; 51: 145–156
- Dillard T., Yedinak C.G., Alumkal J., Fleseriu M.: Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer subtypes. Pituitary, 2010; 13: 29–38
- Dyrka K., Miedziaszczyk M., Szałek E., Łącka K.: Drugs used in viral diseases – their mechanism of action, selected adverse effects and safety during pregnancy and lactation. Postępy Hig. Med. Dośw., 2019; 73: 491–507
- Emens L.A., Cruz C., Eder J.P., Braiteh F., Chung C., Tolaney S.M., Kuter I., Nanda R., Cassier P.A., Delord J.P., Gordon M.S., ElGabry E., Chang C.W., Sarkar I., Grossman W., et al.: Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 study. JAMA Oncol., 2019; 5: 74–82
- Faje A.T., Sullivan R., Lawrence D., Tritos N.A., Fadden R., Klibanski A., Nachtigall L.: Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J. Clin. Endocrinol. Metab., 2014; 99: 4078–4085
- Fassett D.R., Couldwell W.T.: Metastases to the pituitary gland. Neurosurg. Focus., 2004; 16: E8
- Ferlay J., Colombet M., Soerjomataram I., Dyba T., Randi G., Bettio M., Gavin A., Visser O., Bray F.: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer, 2018; 103: 356–387
- Ferrari S.M., Fallahi P., Galetta F., Citi E., Benvenga S., Antonelli A.: Thyroid disorders induced by checkpoint inhibitors. Rev. Endocr. Metab. Disord., 2018; 19: 325–333
- Freeman-Keller M., Kim Y., Cronin H., Richards A., Gibney G., Weber J.S.: Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes. Clin. Cancer Res., 2016; 22: 886–894
- Gauci M.L., Laly P., Vidal-Trecan T., Baroudjian B., Gottlieb J., Madjlessi-Ezra N., Da Meda L., Madelaine-Chambrin I., Bagot M., Basset-Seguin N., Pages C., Mourah S., Boudou P., Lebbé C., Gautier J.F.: Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: A case report and literature review. Cancer Immunol. Immunother., 2017; 66: 1399–1410
- Gharwan H., Groninger H.: Kinase inhibitors and monoclonal antibodies in oncology: Clinical implications. Nat. Rev. Clin. Oncol., 2016; 13: 209–227
- Ha D., Tanaka A., Kibayashi T., Tanemura A., Sugiyama D., Wing J.B., Lim E.L., Teng K.W., Adeegbe D., Newell E.W., Katayama I., Nishikawa H., Sakaguchi S.: Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. Proc. Natl. Acad. Sci. USA, 2019; 116: 609–618
- Haanen J.B., Carbonnel F., Robert C., Kerr K.M., Peters S., Larkin J., Jordan K., ESMO Guidelines Committee: Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2017; 28: iv119–iv142
- Haanen J.B., Robert C.: Immune checkpoint inhibitors. Prog. Tumor Res., 2015; 42: 55–66
- Hafeez U., Gan H.K., Scott A.M.: Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Curr. Opin. Pharmacol., 2018; 41: 114–121
- Hodi F.S., Chesney J., Pavlick A.C., Robert C., Grossman K.F., McDermott D.F., Linette G.P., Meyer N., Giguere J.K., Agarwala S.S., Shaheen M., Ernstoff M.S., Minor D.R., Salama A.K., Taylor M.H., et al.: Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol., 2016; 17: 1558–1568
- Horn L., Mansfield A.S., Szczęsna A., Havel L., Krzakowski M., Hochmair M.J., Huemer F., Losonczy G., Johnson M.L., Nishio M., Reck M., Mok T., Lam S., Shames D.S., Liu J., et al.: First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med., 2018; 379: 2220–2229
- Iglesias P.: Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach. Eur. J. Intern. Med., 2018; 47: 6–13
- Illouz F., Briet C., Cloix L., Le Corre Y., Baize N., Urban T., Martin L., Rodien P.: Endocrine toxicity of immune checkpoint inhibitors: Essential crosstalk between endocrinologists and oncologists. Cancer Med., 2017; 6: 1923–1929
- Imfinzi – Summary of Product Characteristics. https://www.ema.europa.eu/en//documents/product-information/imfizi-epar-product-information_en.pdf (25.09.2020)
- Iwama S., De Remigis A., Callahan M.K., Slovin S.F., Wolchok J.D., Caturegli P.: Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med., 2014; 6: 230ra45
- Iyer P.C., Cabanillas M.E., Waguespack S.G., Hu M.I., Thosani S.N., Lavis V.R., Busaidy N.L., Subudhi S.K., Diab A., Dadu R.: Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid, 2018; 28: 1243–1251
- Joo W.D., Visintin I., Mor G.: Targeted cancer therapy – Are the days of systemic chemotherapy numbered? Maturitas, 2013; 76: 308–314
- Joshi M.N., Whitelaw B.C., Palomar M.T., Wu Y., Carroll P.V.: Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: Clinical review. Clin. Endocrinol., 2016; 85: 331–339
- June C.H., Warshauer J.T., Bluestone J.A.: Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat. Med., 2017; 23: 540–547
- Kalogeras K.T., Nieman L.K., Friedman T.C., Doppman J.L., Cutler G.B. Jr, Chrousos G.P., Wilder R.L., Gold P.W., Yanovski J.A.: Inferior petrosal sinus sampling in healthy subjects reveals a unilateral corticotropin-releasing hormone-induced arginine vasopressin release associated with ipsilateral adrenocorticotropin secretion. J Clin Invest., 1996; 97: 2045–2050
- Katzke V.A., Kaaks R., Kühn T.: Lifestyle and cancer risk. Cancer J., 2015; 21: 104–110
- Keytruda – Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf (25.09.2020)
- Konda B., Nabhan F., Shah M.H.: Endocrine dysfunction following immune checkpoint inhibitor therapy. Curr. Opin. Endocrinol. Diabetes Obes., 2017; 24: 337–347
- Lam K.Y., Lo C.Y.: Metastatic tumours of the adrenal glands: A 30-year experience in a teaching hospital. Clin. Endocrinol., 2002; 56: 95–101
- Lee Y.T., Tan Y.J, Oon C.E.: Molecular targeted therapy: Treating cancer with specificity. Eur. J. Pharmacol., 2018; 834: 188–196
- Liu M., Guo F.: Recent updates on cancer immunotherapy. Precis Clin. Med., 2018; 1: 65–74
- Lupi I., Zhang J., Gutenberg A., Landek-Salgado M., Tzou S.C., Mori S., Caturegli P.: From pituitary expansion to empty sella: Disease progression in a mouse model of autoimmune hypophysitis. Endocrinology, 2011; 152: 4190–4198
- Manohar S., Kompotiatis P., Thongprayoon C., Cheungpasitporn W., Herrmann J., Herrmann S.M.: Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: Meta-analysis. Nephrol. Dial. Transplant., 2019; 34: 108–117
- Marin-Acevedo J.A., Soyano A.E., Dholaria B., Knutson K.L., Lou Y.: Cancer immunotherapy beyond immune checkpoint inhibitors. J. Hematol. Oncol., 2018; 11: 8
- Min L., Hodi F.S., Giobbie-Hurder A., Ott P.A., Luke J.J., Donahue H., Davis M., Carroll R.S., Kaiser U.B.: Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: A retrospective cohort study. Clin. Cancer Res., 2015; 21: 749–755
- Molitch M.E., Clemmons D.R., Malozowski S., Merriam G.R., Vance M.L., Endocrine Society: Evaluation and treatment of adult growth hormone deficiency: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab., 2011; 96: 1587–1609
- Ni J., Qiu L.J., Zhang M., Wen P.F., Ye X.R., Liang Y., Pan H.F., Ye D.Q.: CTLA-4 CT60 (rs3087243) polymorphism and autoimmune thyroid diseases susceptibility: A comprehensive meta-analysis. Endocr. Res., 2014; 39: 180–188
- Oelkers W.: Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism. N. Engl. J. Med., 1989; 321: 492–496
- Opdivo – Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf (25.09.2020)
- Parakh S., King D., Gan H.K., Scott A.M.: Current development of monoclonal antibodies in cancer therapy. Recent Res. Cancer Res., 2020; 214: 1–70
- Pardoll D.M.: The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer, 2012; 12: 252–264
- Persani L., Ferretti E., Borgato S., Faglia G., Beck-Peccoz P.: Circulating thyrotropin bioactivity in sporadic central hypothyroidism. J. Clin. Endocrinol. Metab., 2000; 85: 3631–3635
- Peters C., Brown S.: Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci. Rep., 2015; 35: e00225
- Piranavan P., Li Y., Brown E., Kemp E.H., Trivedi N.: Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. J. Clin. Endocrinol. Metab., 2019; 104: 550–556
- Puar T.H., Stikkelbroeck N.M., Smans L.C., Zelissen P.M., Hermus A.R.: Adrenal crisis: Still a deadly event in the 21st century. Am. J. Med., 2016; 129: 339.e1–9
- Raghavan R., Brady M.L., Sampson J.H.: Delivering therapy to target: Improving the odds for successful drug development. Ther. Deliv., 2016; 7: 457–481
- Rakoff-Nahoum S.: Why cancer and inflammation? Yale J. Biol. Med., 2006; 79: 123–130
- Ruggeri R.M., Campennì A., Giuffrida G., Trimboli P., Giovanella L., Trimarchi F., Cannavò S.: Endocrine and metabolic adverse effects of immune checkpoint inhibitors: An overview (what endocrinologists should know). J. Endocrinol. Invest., 2019; 42: 745–756
- Scott E.S., Long G.V., Guminski A., Clifton-Bligh R.J., Menzies A.M., Tsang V.H.: The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur. J. Endocrinol., 2018; 178: 173–180
- Socinski M.A., Jotte R.M., Cappuzzo F., Orlandi F., Stroyakovskiy D., Nogami N., Rodríguez-Abreu D., Moro-Sibilot D., Thomas C.A., Barlesi F., Finley G., Kelsch C., Lee A., Coleman S., Deng Y., et al.: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med., 2018; 378: 2288–2301
- Song M., Giovannucci E.: Preventable incidence and mortality of carcinoma associated with lifestyle factors among white adults in the United States. JAMA Oncol., 2016; 2: 1154–1161
- Suzuki M., Kato C., Kato A.: Therapeutic antibodies: Their mechanisms of action and the pathological findings they induce in toxicity studies. J. Toxicol. Pathol., 2015; 28: 133–139
- Tecentriq – Summary of Product Characteristics. https://www.ema.europa.eu/en//documents/product-information/tecentriq-epar-product-information_en.pdf (25.09.2020)
- Tolcher A.W.: Antibody drug conjugates: Lessons from 20 years of clinical experience. Ann. Oncol., 2016; 27: 2168–2172
- Toporcov T.N., Wünsch Filho V.: Epidemiological science and cancer control. Clinics, 2018; 73: e627s
- Torino F., Corsello S.M., Salvatori R.: Endocrinological side-effects of immune checkpoint inhibitors. Curr. Opin. Oncol., 2016; 28: 278–287
- U.S. Cancer Statistics Working Group. 1999–2013 Incidence and mortality web-based report. www.cdc.gov/uscs (25.09.2020)
- Venetsanaki V., Boutis A., Chrisoulidou A., Papakotoulas P.: Diabetes mellitus secondary to treatment with immune checkpoint inhibitors. Curr. Oncol., 2019; 26: e111–e114
- Weber J.S., Postow M., Lao C.D., Schadendorf D.: Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist, 2016; 21: 1230–1240
- Weiner L.M., Surana R., Wang S.: Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat. Rev. Immunol., 2010; 10: 317–327
- Win M.A., Thein K.Z., Qdaisat A., Yeung S.C.: Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. Am. J. Emerg. Med., 2017; 35: 1039.e5–1039.e7
- World Health Organization. Cancer fact sheet. http://www.who.int/mediacentre//factsheets/fs297/en/ (25.09.2020)
- Yamazaki N., Kiyohara Y., Uhara H., Fukushima S., Uchi H., Shibagaki N., Tsutsumida A., Yoshikawa S., Okuyama R., Ito Y., Tokudome T.: Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Cancer Chemother. Pharmacol., 2015; 76: 997–1004
- Yervoy-Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf (25.09.2020)
- Zhao C., Tella S.H., Del Rivero J., Kommalapati A., Ebenuwa I., Gulley J., Strauss J., Brownell I.: Anti-PD-L1 treatment induced central diabetes insipidus. J. Clin. Endocrinol. Metab., 2018; 103: 365–369
DOI: https://doi.org/10.5604/01.3001.0014.8889 | Journal eISSN: 1732-2693
Language: English
Page range: 317 - 327
Submitted on: Nov 15, 2020
Accepted on: Feb 26, 2021
Published on: May 18, 2021
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
Related subjects:
© 2021 Kamil Dyrka, Daria Witasik, Agata Czarnywojtek, Katarzyna Łącka, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.